Immusoft Corporation is a pre-clinical gene therapy company structured around treatment of diseases using its technology platform designated Immune System Programming (ISP). ISP effectively is designed to instruct a patients cells to produce gene-encoded medicines (biologics). Cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. Technical challenges, complex purification steps and frequent injections for patients are some of the challenges of biologic drug therapies. With small patient populations, rare diseases have significant commercial hurdles and can be very high cost. Cell therapy with ISP is a way to deliver biologic drug therapies. With an exclusive license for the core technology from Caltech and patent protection for the ISP platform. Headquartered in Seattle but having a facility in San Francisco., Immusoft has work closely with prominent collaborators from the Fred Hutchinson Cancer Research Center in Seattle, and the University of Minnesota Medical Center to conduct the firm's first human trials to treat MPS .
